Chloe Danquah’s Post

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8

Proud to announce that Mermaid Bio GmbH and the CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October 2024. Sophisticated investors, decision makers and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEOs, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8 hashtag #ceos hashtag #investors hashtag #fundraising Activate to view larger image,

𝐋𝐀𝐔𝐍𝐂𝐇𝐈𝐍𝐆 𝐒𝐎𝐎𝐍 👉 "𝐄𝐂𝐎𝐂𝐀𝐑𝐄 𝐃𝐈𝐕𝐈𝐒𝐈𝐎𝐍" "𝘾𝙖𝙧𝙙𝙞𝙖𝙘-𝘿𝙞𝙖𝙗𝙚𝙩𝙞𝙘 𝙎𝙚𝙜𝙢𝙚𝙣𝙩" 👉 "𝑻𝒐 𝑺𝒆𝒓𝒗𝒆 𝑻𝒉𝒆 𝑯𝒖𝒎𝒂𝒏𝒊𝒕𝒚"  "𝑰𝒏𝒕𝒓𝒐𝒅𝒖𝒄𝒊𝒏𝒈 𝒕𝒉𝒆 𝑴𝒐𝒔𝒕 𝑬𝒄𝒐𝒏𝒐𝒎𝒊𝒄𝒂𝒍 𝒂𝒏𝒅 𝑪𝒐𝒔𝒕-𝑬𝒇𝒇𝒆𝒄𝒕𝒊𝒗𝒆 𝑸𝒖𝒂𝒍𝒊𝒕𝒚 𝑴𝒆𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔"  Skycare Pharma is excited to announce the upcoming launch of its Ecocare Division, focused on providing Cardiac-Diabetic medications at highly economical prices. This initiative aims to make essential treatments accessible to all, particularly those facing financial hardships.  Our mission is to ensure that everyone can obtain the medications they need at a price they can afford. We are proud to introduce the Cardiac-Diabetic division, addressing the growing prevalence of these conditions across the nation.  The Ecocare Division is dedicated to supporting individuals who struggle to afford necessary medications due to financial constraints.

Thank you Teresa Harris Graham for sharing! Roche's vision for establishing collaborations to improve care has transcended Basel, reaching multiple geographies, thanks to your support to the Movement Health Foundation too. The partnerships with corporations from diverse industries, ministries of health, and local leaders, achieved the following outcomes in 2024: ✅ Peru & South Africa: Our Empowering Women to Live Cancer-Free projects were recognized as a CGI commitment. ✅ Mexico: Published a Health Data Dashboard for 8.9 million beneficiaries in Mexico City, transforming decision-making for the Mexico City Health Secretariat. ✅ Ghana: The Digital Pharmacy Platform secured reimbursement from the Ghana National Health Insurance Scheme for enhanced hypertension care for 87,000 patients, enrolling 70 care centers. ✅ Chile: the National Health Data Governance open consultations to scale up digital health were held. ✅ Bulgaria: Established a tri-partite collaboration agreement with the Helsinki University Hospital (HUS) and the Bulgaria National Health Information System (NHIS), leveraging Finnish expertise for the National Digitalized Patient Journey to ensure reliable, detailed, and verified treatment information for long-term and chronic conditions.

Congratulations to Babson Diagnostics for being named Medtech Company of the Year by both MD+DI Editors and Readers!! This sampling of survey comments by readers really sums it up: - Great mission, doing things that others couldn't - #Groundbreaking technology and legitimate capillary testing could be a game changer for patients - #Accessibility. I wish this had been in place when I had to continually take my mom to labs for bloodwork. - Making routine blood testing more accessible and #convenient will have a profound impact on the entire #healthcare system. They achieved commercial readiness and launch this year, and clinicians and providers all rave about the experience so far. - Potential massive impact in cost and convenience Truly exciting, game-changing work underway! Editors' Choice announcement: https://lnkd.in/eCSUg9tu Readers' Choice announcement: https://lnkd.in/e-JJCpwn #VC #patientcare #innovation #BackedByEmerald #patientexperience #changetheworld

Proud to announce that Mermaid Bio GmbH and their CEO Ranja Salvamoser will be presenting at Meet the DONs Virtual Event on the 24th of October. Sophisticated investors, decision makers, and opportunities are all brought together by this special online experience. Due in part to COVID, we have welcomed over 1,500 virtual attendees since our launch in 2020. A true meeting place for CEO's, Founders, decision makers and sophisticated investors. Mermaid Bio’s Intrabodies represent a novel precision-medicine approach that can tackle notoriously difficult targets and is piloted directly to the tissue of interest to avoid damaging side effects. Intrabodies The power of antibodies and targeted drug delivery, wrapped in one. By pairing antibodies with intracellular delivery, Intrabodies bring the strength of antibodies into diseased cells, without damaging healthy tissues. Beyond giving patients new hope, our purpose is to restore their quality of life If you are a Founder, CEO or sophisticated investor register for free with this link - https://lnkd.in/eRMU3CEH Are you a healthcare business seeking funding if so, feel free to submit your opportunity to our network via this link - https://lnkd.in/ep8Bqsb8 #Biotech #BiotechLeaders #LifeSciences #Healthcare #BiotechInvestors #BiotechStartups #MedTech

What role can #Genetherapy play in the prevalent disease space? Here from Maryland-based Addimmune™ about this and more at this year’s CMO summit 360. #HIVCure #CellGeneTherapy #Celltherapy

I am thrilled to announce that SHS Capital, in partnership with GENUI, has invested in ROTOP Pharmaka GmbH, a leading European manufacturer and CDMO of radiopharmaceuticals. This strategic investment aims to significantly expand ROTOP's development, laboratory, and production capacities, particularly in radioligand therapy (RLT). By enhancing these capabilities, we are committed to advancing diagnostic and therapeutic solutions that offer highly targeted efficacy, minimizing harm to healthy tissues. Our collaboration with ROTOP not only accelerates the availability of cutting-edge radiopharmaceuticals but also strengthens Europe's and Germany's ability to address complex diseases with locally sourced, critical medical supplies. This initiative underscores our dedication to building European healthcare champions and improving patient care across the region. We look forward to supporting ROTOP's growth and contributing to the development of innovative healthcare solutions that benefit patients and families throughout Europe. The transaction also underscores SHS Capital's positioning as partner of choice for investments in highly regulated and complex healthcare settings in Europe and especially the DACH region. #BuildingEuropeanHealthcareChampions #HealthcareInnovation #Radiopharmaceuticals #PatientCare #EuropeanHealthcare #ROTOP #SHSCapital #GENUI Jens Junker, Dr. Wilhelm Zörgiebel, Prof. Dr. med. Jörg Felix Dr. Cornelius Maas, Guillaume Balz, Hannes Kempter Nicolas Kollmann, Oliver Serg, Sarah Kaiser, Sumeet Gulati

A strong market access strategy aims to effectively convey an evidence-based value story to payers, ensuring rare disease patients have access to essential treatments. However, generating solid evidence can be challenging. By engaging directly with patients, pharma and biotech companies can gather crucial data that strengthens the evidence supporting their market access efforts. To learn more about the importance of co-creating successful market access strategies for rare disease treatments, we spoke with Annabel de Maria Bosch, Chief Patient Officer, and Pepi Hurtado-Lopez, Managing Partner, Market Access & Pricing. Read the full interview: https://lnkd.in/gz2Ti-HH